Many women with breast cancer choose to undergo reconstruction after mastectomy. Of those women, some opt for nipple sparing surgeries while others do not. “Those who choose to save their nipples are often disappointed when the tissue dies or no longer functions as it did before surgery,” writes one survivor. “But why are nipples so important?”
Opdivo was the first PD-1 inhibitor to show durable responses in patients with esophageal squamous cell carcinoma.
Recent research found that breast implants with a specific texture tended to result in a lower level of inflammation and immune reactions than other implants.
Learn the differences between sunscreen types and what to look for.
One team of oncology nurses rose above the challenges during the pandemic to continually care for their patients in different ways.
A woman describes the scars that cancer and other life events have left her with.
A colleague details how an oncology nurse goes above and beyond no matter the task, especially during the COVID-19 pandemic.
One colleague describes her fellow nurse as someone who puts patients at ease during treatment.
Thanks to ongoing research and clinical trials, it seems that there are always new immunotherapies emerging.
A pancreatic cancer survivor describes the ways in which undergoing cancer treatment is comparable to summiting Mount Everest.
From a dance tribute performed by Kevin Boseman, late actor Chadwick Boseman’s brother to the humorous coloring book a woman created during treatment for cancer, here’s what’s happening in the cancer landscape this week.
The combination of Gleevec and Xpovio demonstrated some promising results in a small group of patients with a rare form of advanced gastrointestinal cancer whose disease had failed to respond to prior first-line treatment with Gleevec.
As the cancer treatment landscape continues to expand, patients and their caregivers should be aware of the various clinical trials currently being conducted — including studies they can possibly join.
At a median follow-up of almost two years, 88.5% of patients remained on study treatment.
A breast cancer survivor writes a poem about a symbol of reassurance she saw while fatigued from cancer treatments.
In this episode of the “CURE® Talks Cancer” podcast, Dr. Thomas Marron of the Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai in New York discusses the exciting future of cancer vaccines.
Recent findings merit further study of the immunosuppressive drug as therapy in patients with multiple myeloma.
Monjuvi and Revlimid attained extended remission and improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma.
The survival benefit obtained with Ibrance plus Faslodex persisted over a median follow-up of 73.3 months in patients with HR-positive, HER2-negative advanced breast cancer.
A cancer survivor explains how she is approaching her reentry into the world after COVID-19 restrictions have been lifted.
Recent findings showed that the cost of cancer care affects nearly half of women with gynecologic cancer, with younger and/or non-white patients at higher risk for financial toxicity.
The upcoming symposium will give members of the colorectal cancer community a chance to spread awareness and discuss prevention and treatment strategies for the disease in younger age groups.
Results from a recent study strongly support a treatment regimen of Darzalex with Revlimid and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.
Patients with metastatic KRAS G12C mutated non-small cell lung cancer now have another treatment option if they previously failed at least one line of therapy.
A mother describes how her daughter discovered a lump that led to a breast cancer diagnosis.
From the rapid vaccine development to heart risks and delaying immunization, we spoke with an infectious disease expert on common worries people have about getting the COVID-19 vaccine.
The findings open up the door for a fourth-line treatment option in patients with advanced gastrointestinal stromal tumors with disease progression.
On behalf of the Head and Neck Cancer Alliance, Dr. Michael Moore spoke with CURE® about emerging therapies that potentially offer exciting new options for the future.
On social media, CURE® recently asked its readers to share what was the most meaningful thing someone has said to them during their cancer journey. Here’s what they shared.
“Each person living with cancer has a story to tell, but some may choose not to share it because of its personal nature,” writes one survivor. In this piece, she describes how she found a way to give her story words.
